title: Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin.
abstract: Paclitaxel and carboplatin (TC) chemotherapy is an effective and well-tolerated regimen against advanced endometrial cancer. Organic anion transporting polypeptide 1B3 (OATP1B3) and copper transporter 1 (CTR1) are critical for the uptake of paclitaxel and carboplatin, respectively. This study aimed to address the prognostic impact of OATP1B3 and CTR1 in endometrial cancer patients treated with adjuvant TC chemotherapy. We immunohistochemically evaluated the expressions of OATP1B3 and CTR1 in 47 stage III endometrial cancers. The high expression levels of OATP1B3 were significantly correlated with type I tumor (P = 0.0005). In univariate analysis, high expression levels of OATP1B3 (P = 0.047) and CTR1 (P = 0.009) were significantly associated with longer disease-free survival (DFS) and longer overall survival (OS), respectively. The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer DFS (P = 0.058) and significantly longer OS (P = 0.003) sin the univariate analysis. Combined OATP1B3/CTR1 expression was the sole independent prognostic factor for longer OS in the multivariate analysis (P = 0.013). Our findings suggest that combined OATP1B3/CTR1 expression is a possible predictive/prognostic factor for a good outcome in stage III endometrial cancer patients treated with adjuvant TC chemotherapy.
authors.affiliation: Department of Pathology, Kanagawa Cancer Center Hospital, 1-1-2 Nakao, Asahi, Yokohama 241-0815, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Ogane
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuda
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Kameda
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Yokose
authors.forename: Hisamori
authors.initials: H
authors.lastname: Kato
authors.forename: Ayumi
authors.initials: A
authors.lastname: Itoh
authors.forename: Satoshi
authors.initials: S
authors.lastname: Nishino
authors.forename: Yumi
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: Shingo
authors.initials: S
authors.lastname: Kamoshida
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D016190:Carboplatin / Q000627:therapeutic use*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D027682:Cation Transport Proteins / Q000235:genetics* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D000079923:Copper Transporter 1; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D029362:Organic Anion Transporters, Sodium-Independent / Q000235:genetics* / Q000378:metabolism; D017239:Paclitaxel / Q000627:therapeutic use*; D011379:Prognosis; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D027682:Cation Transport Proteins; D000079923:Copper Transporter 1; D029362:Organic Anion Transporters, Sodium-Independent; C490079:SLC31A1 protein, human; C421209:SLCO1B3 protein, human; D000074542:Solute Carrier Organic Anion Transporter Family Member 1B3; D016190:Carboplatin; D017239:Paclitaxel